Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 6Radiosurgery 5Docetaxel 5enzalutamide 4darolutamide 3Radiotherapy 3Everolimus 3Androgen Antagonists 3relugolix 2luprolide acetate gel depot 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Image-Guided 2Radiofrequency Ablation 2Panobinostat 2Leuprolide 2Abiraterone Acetate 2trastuzumab deruxtecan 1talazoparib 1spartalizumab 1siremadlin 1sipuleucel-T 1sargramostim 1resiquimod 1polysaccharide-K 1poly ICLC 1palbociclib 1olaparib 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Prodrugs × Genitourinary × Clear all
NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡